The North America Actinic Keratosis Treatment Market would witness market growth of 3.7% CAGR during the forecast period (2022-2028).
Anyone who spends a significant amount of time outside without protection runs the possibility of creating one or more AKs, regardless of the weather. UV rays may penetrate through clouds, even when it is cloudy. The chance of getting AKs is increased if the immune system is compromised. Medical procedures like immunosuppressive or chemotherapy therapy might impair the immune system.
If someone has a disease like leukemia, lymphoma, or HIV, the immune system may also be compromised. The immune system is suppressed by prolonged UV exposure, which lowers its capacity to repair more damage. Although anybody can get AKs, those with fair skin are more likely to do so, especially those with blond or red hair, green or blue eyes, or skin that gets freckles or burns readily.
Because UV harm to the skin builds up over time, the total lifetime impact increases with age. This explains the prevalence of AKs in individuals over the age of 40. There is a growing use of self-administered therapy and the accessibility of options for home-based therapy. Actinic keratosis is typically treated topically using topical creams containing fluorouracil, a chemotherapy agent, as well as other medications including Imiquimod (INN) gels and diclofenac, an analgesic.
With the simple availability of improved treatments in North America, including combination therapy and monotherapy, actinic keratosis is becoming more common and there is a rising need for minimally invasive procedures. The increasing cancer research initiatives in North America are also anticipated to increase the requirement for actinic keratosis treatments. This is because these treatments are essential for preventing the growth of cancer tumors and easing the burden that rising cancer incidence has on the healthcare system.
The US market dominated the North America Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,190.5 Million by 2028.The Canada market is poised to grow at a CAGR of 6.1% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Actinic Keratosis Treatment Market is Estimated to reach $8 Billion by 2028, at a CAGR of 4.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Nucleoside Metabolic Inhibitor
- NSAIDs
- Immune Response Modifiers
- Photoenhancers
- Others
By Therapy
- Surgery
- Topical
- Photodynamic Therapy
By End-use
- Hospitals
- Private Clinics
- Homecare
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Almirall, S.A
- LEO Pharma A/S
- Biofrontera AG
- Sun Pharmaceuticals Industries Ltd.
- 3M Company
- Bausch Health Companies, Inc.
- Novartis AG
- Viatris, Inc.
- Galderma S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Actinic Keratosis Treatment Market, by Drug Class
1.4.2 North America Actinic Keratosis Treatment Market, by Therapy
1.4.3 North America Actinic Keratosis Treatment Market, by End-use
1.4.4 North America Actinic Keratosis Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Actinic Keratosis Treatment Market by Drug Class
3.1 North America Nucleoside Metabolic Inhibitor Market by Country
3.2 North America NSAIDs Market by Country
3.3 North America Immune Response Modifiers Market by Country
3.4 North America Photoenhancers Market by Country
3.5 North America Others Market by Country
Chapter 4. North America Actinic Keratosis Treatment Market by Therapy
4.1 North America Surgery Market by Country
4.2 North America Topical Market by Country
4.3 North America Photodynamic Therapy Market by Country
Chapter 5. North America Actinic Keratosis Treatment Market by End-use
5.1 North America Hospitals Market by Country
5.2 North America Private Clinics Market by Country
5.3 North America Homecare Market by Country
5.4 North America Others Market by Country
Chapter 6. North America Actinic Keratosis Treatment Market by Country
6.1 US Actinic Keratosis Treatment Market
6.1.1 US Actinic Keratosis Treatment Market by Drug Class
6.1.2 US Actinic Keratosis Treatment Market by Therapy
6.1.3 US Actinic Keratosis Treatment Market by End-use
6.2 Canada Actinic Keratosis Treatment Market
6.2.1 Canada Actinic Keratosis Treatment Market by Drug Class
6.2.2 Canada Actinic Keratosis Treatment Market by Therapy
6.2.3 Canada Actinic Keratosis Treatment Market by End-use
6.3 Mexico Actinic Keratosis Treatment Market
6.3.1 Mexico Actinic Keratosis Treatment Market by Drug Class
6.3.2 Mexico Actinic Keratosis Treatment Market by Therapy
6.3.3 Mexico Actinic Keratosis Treatment Market by End-use
6.4 Rest of North America Actinic Keratosis Treatment Market
6.4.1 Rest of North America Actinic Keratosis Treatment Market by Drug Class
6.4.2 Rest of North America Actinic Keratosis Treatment Market by Therapy
6.4.3 Rest of North America Actinic Keratosis Treatment Market by End-use
Chapter 7. Company Profiles
7.1 Almirall, S.A
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Product Launches and Product Expansions:
7.2 LEO Pharma A/S
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Biofrontera AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Sun Pharmaceuticals Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 3M Company
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 SWOT Analysis
7.6 Bausch Health Companies, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Galderma S.A.
7.9.1 Company Overview
TABLE 1 North America Actinic Keratosis Treatment Market, 2018 - 2021, USD Million
TABLE 2 North America Actinic Keratosis Treatment Market, 2022 - 2028, USD Million
TABLE 3 North America Actinic Keratosis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 4 North America Actinic Keratosis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 5 North America Nucleoside Metabolic Inhibitor Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Nucleoside Metabolic Inhibitor Market by Country, 2022 - 2028, USD Million
TABLE 7 North America NSAIDs Market by Country, 2018 - 2021, USD Million
TABLE 8 North America NSAIDs Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Immune Response Modifiers Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Immune Response Modifiers Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Photoenhancers Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Photoenhancers Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Actinic Keratosis Treatment Market by Therapy, 2018 - 2021, USD Million
TABLE 16 North America Actinic Keratosis Treatment Market by Therapy, 2022 - 2028, USD Million
TABLE 17 North America Surgery Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Surgery Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Topical Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Topical Market by Country, 2022 - 2028, USD Million
TABLE 21 North America Photodynamic Therapy Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Photodynamic Therapy Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Actinic Keratosis Treatment Market by End-use, 2018 - 2021, USD Million
TABLE 24 North America Actinic Keratosis Treatment Market by End-use, 2022 - 2028, USD Million
TABLE 25 North America Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Private Clinics Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Private Clinics Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Homecare Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Homecare Market by Country, 2022 - 2028, USD Million
TABLE 31 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 32 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 33 North America Actinic Keratosis Treatment Market by Country, 2018 - 2021, USD Million
TABLE 34 North America Actinic Keratosis Treatment Market by Country, 2022 - 2028, USD Million
TABLE 35 US Actinic Keratosis Treatment Market, 2018 - 2021, USD Million
TABLE 36 US Actinic Keratosis Treatment Market, 2022 - 2028, USD Million
TABLE 37 US Actinic Keratosis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 38 US Actinic Keratosis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 39 US Actinic Keratosis Treatment Market by Therapy, 2018 - 2021, USD Million
TABLE 40 US Actinic Keratosis Treatment Market by Therapy, 2022 - 2028, USD Million
TABLE 41 US Actinic Keratosis Treatment Market by End-use, 2018 - 2021, USD Million
TABLE 42 US Actinic Keratosis Treatment Market by End-use, 2022 - 2028, USD Million
TABLE 43 Canada Actinic Keratosis Treatment Market, 2018 - 2021, USD Million
TABLE 44 Canada Actinic Keratosis Treatment Market, 2022 - 2028, USD Million
TABLE 45 Canada Actinic Keratosis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 46 Canada Actinic Keratosis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 47 Canada Actinic Keratosis Treatment Market by Therapy, 2018 - 2021, USD Million
TABLE 48 Canada Actinic Keratosis Treatment Market by Therapy, 2022 - 2028, USD Million
TABLE 49 Canada Actinic Keratosis Treatment Market by End-use, 2018 - 2021, USD Million
TABLE 50 Canada Actinic Keratosis Treatment Market by End-use, 2022 - 2028, USD Million
TABLE 51 Mexico Actinic Keratosis Treatment Market, 2018 - 2021, USD Million
TABLE 52 Mexico Actinic Keratosis Treatment Market, 2022 - 2028, USD Million
TABLE 53 Mexico Actinic Keratosis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 54 Mexico Actinic Keratosis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 55 Mexico Actinic Keratosis Treatment Market by Therapy, 2018 - 2021, USD Million
TABLE 56 Mexico Actinic Keratosis Treatment Market by Therapy, 2022 - 2028, USD Million
TABLE 57 Mexico Actinic Keratosis Treatment Market by End-use, 2018 - 2021, USD Million
TABLE 58 Mexico Actinic Keratosis Treatment Market by End-use, 2022 - 2028, USD Million
TABLE 59 Rest of North America Actinic Keratosis Treatment Market, 2018 - 2021, USD Million
TABLE 60 Rest of North America Actinic Keratosis Treatment Market, 2022 - 2028, USD Million
TABLE 61 Rest of North America Actinic Keratosis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 62 Rest of North America Actinic Keratosis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 63 Rest of North America Actinic Keratosis Treatment Market by Therapy, 2018 - 2021, USD Million
TABLE 64 Rest of North America Actinic Keratosis Treatment Market by Therapy, 2022 - 2028, USD Million
TABLE 65 Rest of North America Actinic Keratosis Treatment Market by End-use, 2018 - 2021, USD Million
TABLE 66 Rest of North America Actinic Keratosis Treatment Market by End-use, 2022 - 2028, USD Million
TABLE 67 Key Information – Almirall, S.A
TABLE 68 key information – LEO Pharma A/S
TABLE 69 Key Information – Biofrontera AG
TABLE 70 Key Information – Sun Pharmaceuticals Industries Ltd.
TABLE 71 Key Information – 3M Company
TABLE 72 key information – Bausch Health Companies, Inc.
TABLE 73 Key Information – Novartis AG
TABLE 74 key information – Viatris, Inc.
TABLE 75 Key Information – Galderma S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Almirall, S.A
FIG 3 SWOT Analysis: 3M Company